Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | BCL9 | O00512 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271951 | 0.86 | GAA (0.53) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL7063519 | 0.80 | GAA (0.65) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL8578508 | 0.75 | GAA (0.59) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL8741192 | 0.74 | ALDH1A1 (0.60) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL9486189 | 0.74 | GAA (0.57) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL3989423 | 0.74 | GAA (0.62) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL850563 | 0.74 | GAA (0.47) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL3502469 | 0.73 | BCL9 (0.42) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL4661270 | 0.73 | GAA (0.61) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL956911 | 0.73 | GAA (0.61) | GAABCL9CTNNB1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 884 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240052005-A1 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | ANASTASIS BIOTEC LIMITED (GB) | 2024-02-15 | — | — | US | claimed |
| EP-1534734-B1 | METHOD FOR THE SYNTHESIS AND SELECTIVE BIOCATALYTIC MODIFICATION OF PEPTIDES, PEPTIDE MIMETICS AND PROTEINS | ROCHE DIAGNOSTICS GMBH (DE) | 2008-05-07 | — | — | EP | claimed |
| US-20060149035-A1 | Method for the synthesis and selective biocatalytic modification of peptides, peptide mimetics and proteins | ROCHE DIAGNOSTICS GMBH (DE) | 2006-07-06 | — | — | US | claimed |
| EP-1534734-A1 | METHOD FOR THE SYNTHESIS AND SELECTIVE BIOCATALYTIC MODIFICATION OF PEPTIDES, PEPTIDE MIMETICS AND PROTEINS | BOEHRINGER MANNHEIM GMBH (DE) | 2005-06-01 | — | — | EP | claimed |
| WO-2004024751-A1 | METHOD FOR THE SYNTHESIS AND SELECTIVE BIOCATALYTIC MODIFICATION OF PEPTIDES, PEPTIDE MIMETICS AND PROTEINS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-25 | — | — | WO | claimed |
| EP-4746899-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH TROP-2 TARGETING ADC | Iovance Biotherapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122036912-A | Cytokine conjugates for the treatment of proliferative and infectious diseases | 辛索克斯公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4735602-A2 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116914-A1 | METHODS OF GENERATING NANOARRAYS AND MICROARRAYS | NAUTILUS SUBSIDIARY INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109989-A1 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS AND IDENTIFICATION OF COVALENT APTAMERS | UNIV HAWAII (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2001022922-A2 | ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1085011-A1 | Novel polyamine analogues as therapeutic and diagnostic agents | ORIDIGM CORPORATION (US) | 2001-03-21 | — | — | EP | disclosed |
| US-6172261-B1 | BIOSYNTHESIS USING CHAIN EXTENSION | ORIDIGM CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-1001927-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| US-5965106-A | ADMINISTERING TARGETING MOIETY COUPLED TO AFFINITY COMPONENT, WHEREIN TARGETING MOIETY HAS AFFINITY FOR BINDING SITES IN TARGET AREA, AND BINDING PARTNER TO AFFINITY COMPONENT COUPLED TO FUNCTIONAL MOIETY TO LOCALIZE FUNCTIONAL MOIETY IN TARGET | PERIMMUNE HOLDINGS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0938675-A1 | ANALYSIS OF CARBOHYDRATES | AMERSHAM INTERNATIONAL plc (GB) | 1999-09-01 | — | — | EP | disclosed |
| WO-1999003823-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998015829-A1 | ANALYSIS OF CARBOHYDRATES | AMERSHAM INTERNATIONAL PLC (GB) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116914-A1 | METHODS OF GENERATING NANOARRAYS AND MICROARRAYS | SPPL2B, SNAP29, SPPL2A | GAA 4642/4885BCL9 763/4885CTNNB1 2762/4885 |
| US-20260109989-A1 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS AND IDENTIFICATION OF COVALENT APTAMERS | DNMT3A, PCNA, DNMT3L | GAA 3993/4885BCL9 792/4885CTNNB1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.